Skip to main content
Signal8

BriaCell Therapeutics Corp. (BCTXL)

BriaCell Therapeutics Corp. is a clinical-stage biotechnology company, which engages in the development of novel immunotherapies to transform cancer care. It currently advancing its Bria-IMT™ targeted immunotherapy in combination with an immune check point inhibitor in a pivotal 1 Phase 3 study in metastatic breast cancer. The company was founded by Charles L. Wiseman and Isaac Benjamin Maresky on July 26, 2006 and is headquartered in West Vancouver, Canada.

Sector: Pharmaceutical Preparations

Industry: Biotechnology

BriaCell Therapeutics Corp. logo

BriaCell Therapeutics Corp.

NASDAQ:BCTXLSub-class of BCTXHealthcare
-2.44%$0.8000
CLOSED
Mkt Cap$6.99M
EV-
Float8.72M
O/S8.73M
VOL79K sh
$ Vol$63K
RVOL4.64×
Inst Own-
SI0.1%
Net Cash/Sh-
Dilution
BriaCell Therapeutics Corp. logoNASDAQ:BCTXLClosed$0.8000-2.44%
FormDescription
10-K
8-K
7.01,9.01
10-Q
8-K
424B5
8-K
7.01,9.01
10-Q
Quarterly Report
8-K
5.07
25-NSE
SEC Filing
8-K
8.01,9.01
DEF 14A
Definitive Proxy Statement
13G
Beneficial Ownership Report
8-K
1.01,8.01,9.01
424B4
Prospectus
EFFECT
Notice of Effectiveness
S-1MEF
SEC Filing
CERT
SEC Filing
8-A12B
SEC Filing
CORRESP
SEC Filing
CORRESP
SEC Filing
CORRESP
SEC Filing
CORRESP
SEC Filing
8-K
7.01,9.01
FWP
SEC Filing
S-1
Registration Statement

1-25 of 324

…
    BriaCell Therapeutics Corp. (BCTXL) SEC Filings | Signal8